• LongBio Pharma (Suzhou) proposed adopting an H Share Option Scheme, an H Share Incentive Scheme.
• Equity awards could be settled via new H-share issuance, treasury shares, or secondary-market purchases via a trustee.
• Aggregate cap set at 10% of issued shares, excluding treasury shares, measured at shareholder approval of the limit.
• Board resolution dated July 15, 2026; rollout remains subject to shareholder approval at an extraordinary general meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longbio Pharma (Suzhou) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260716-12245941), on July 15, 2026, and is solely responsible for the information contained therein.